34
Participants
Start Date
September 30, 2006
Primary Completion Date
July 31, 2011
Study Completion Date
July 31, 2013
filgrastim
given subcutaneously
pegfilgrastim
given subcutaneously
rituximab
given IV
cyclophosphamide
given IV
cytarabine
given intrathecally
doxorubicin hydrochloride
given IV
etoposide
given IV
ifosfamide
given IV
leucovorin calcium
given IV
liposomal cytarabine
given intrathecally
methotrexate
given intrathecally
therapeutic hydrocortisone
given intrathecally
vincristine sulfate
given IV
Memorial Sloan-Kettering Cancer Center, New York
Albert Einstein Cancer Center at Albert Einstein College of Medicine, The Bronx
Pennsylvania Oncology Hematology Associates, Incorporated - Philadelphia, Philadelphia
West Virginia University Health Sciences Center - Charleston, Charleston
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, St Louis
Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center, Seattle
Rebecca and John Moores UCSD Cancer Center, La Jolla
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles
UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles
UCSF Medical Center at Parnassus, San Francisco
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Beth Israel Deaconess Medical Center, Boston
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus
National Cancer Institute (NCI)
NIH
The Emmes Company, LLC
INDUSTRY
AIDS Malignancy Consortium
NETWORK